Protein Official symbol | CYBA |
Aliases | CYBA |
Chromosomal Location | 16 |
Length | 195 |
Uniprot ID | P13498 |
EC number | None |
Protein family Information(Pfam) | PF05038; |
PDB id | 1WLP; |
InterPro ID | IPR007732; |
dbSNP | rs28941476 rs179363891 rs179363891 rs179363890 rs179363893 rs4673 rs104894513 rs179363892 rs104894510 rs104894514 rs179363894 rs119103269 rs104894515 rs72667005 rs1049254 rs72667006 |
Protein 1 | Protein 2 | Combine Score |
---|---|---|
NCF2 | NCF1 | 0.9990000000000001 |
CYBB | NCF1 | 0.998 |
CYBB | NCF2 | 0.998 |
NCF1 | CYBA | 0.997 |
NCF2 | CYBA | 0.997 |
CYBB | CYBA | 0.997 |
NOX1 | CYBA | 0.996 |
NCF4 | CYBB | 0.996 |
NOXO1 | NOXA1 | 0.995 |
NCF4 | CYBA | 0.9940000000000001 |
NOX4 | CYBA | 0.9940000000000001 |
NOX1 | NOXA1 | 0.993 |
NOXA1 | NCF1 | 0.991 |
NOXO1 | CYBA | 0.99 |
NCF2 | RAC2 | 0.9890000000000001 |
CYBA | NOX3 | 0.9890000000000001 |
CYBB | RAC2 | 0.987 |
NOXO1 | NOX1 | 0.986 |
NOX1 | NCF1 | 0.986 |
NCF4 | RAC2 | 0.985 |
NCF1 | RAC2 | 0.9840000000000001 |
NOXA1 | NOX3 | 0.98 |
NCF4 | NCF2 | 0.98 |
NOXA1 | CYBA | 0.9790000000000001 |
NCF1 | NOX3 | 0.978 |
NCF2 | NOX3 | 0.978 |
NOX1 | NCF2 | 0.977 |
CYBA | RAC2 | 0.9740000000000001 |
NCF4 | NCF1 | 0.972 |
NCF4 | NOX1 | 0.946 |
NOXO1 | NCF2 | 0.943 |
NOXO1 | CYBB | 0.941 |
CYBB | NOXA1 | 0.9390000000000001 |
NCF1 | NOX4 | 0.9329999999999999 |
NCF4 | NOXA1 | 0.9229999999999999 |
NOX1 | RAC2 | 0.9229999999999999 |
NCF2 | NOX4 | 0.92 |
NOXO1 | NCF4 | 0.919 |
NCF2 | NOXA1 | 0.9179999999999999 |
CYBB | NOX4 | 0.9129999999999999 |
NOXO1 | NOX3 | 0.8690000000000001 |
NOXA1 | NOX4 | 0.8370000000000001 |
NOXO1 | NOX4 | 0.831 |
NOX1 | NOX4 | 0.83 |
NCF4 | NOX4 | 0.8220000000000001 |
NCF4 | NOX3 | 0.8109999999999999 |
CYBB | NOX1 | 0.8109999999999999 |
NOXO1 | NCF1 | 0.797 |
NOXA1 | RAC2 | 0.685 |
RAC2 | NOX3 | 0.565 |
NOX4 | RAC2 | 0.5379999999999999 |
NOXO1 | RAC2 | 0.489 |
NOX4 | NOX3 | 0.451 |
# | 4688 (NCF2) | 1536 (CYBB) | 653361 (NCF1) | 27035 (NOX1) | 4689 (NCF4) | 124056 (NOXO1) | 50507 (NOX4) | 10811 (NOXA1) | 1535 (CYBA) | 5880 (RAC2) |
---|---|---|---|---|---|---|---|---|---|---|
4688 (NCF2) | 1.00 | 0.70 | 0.66 | 0.52 | 0.60 | 0.64 | 0.60 | 0.67 | 0.80 | 0.15 |
1536 (CYBB) | 0.70 | 1.00 | 0.69 | 0.68 | 0.51 | 0.55 | 0.88 | 0.54 | 0.84 | 0.49 |
653361 (NCF1) | 0.66 | 0.69 | 1.00 | 0.55 | 0.72 | 0.80 | 0.65 | 0.70 | 0.79 | 0.24 |
27035 (NOX1) | 0.52 | 0.68 | 0.55 | 1.00 | 0.45 | 0.51 | 0.67 | 0.62 | 0.65 | 0.39 |
4689 (NCF4) | 0.60 | 0.51 | 0.72 | 0.45 | 1.00 | 0.83 | 0.45 | 0.74 | 0.57 | 0.19 |
124056 (NOXO1) | 0.64 | 0.55 | 0.80 | 0.51 | 0.83 | 1.00 | 0.50 | 0.80 | 0.59 | 0.27 |
50507 (NOX4) | 0.60 | 0.88 | 0.65 | 0.67 | 0.45 | 0.50 | 1.00 | 0.49 | 0.72 | 0.49 |
10811 (NOXA1) | 0.67 | 0.54 | 0.70 | 0.62 | 0.74 | 0.80 | 0.49 | 1.00 | 0.67 | 0.15 |
1535 (CYBA) | 0.80 | 0.84 | 0.79 | 0.65 | 0.57 | 0.59 | 0.72 | 0.67 | 1.00 | 0.15 |
5880 (RAC2) | 0.15 | 0.49 | 0.24 | 0.39 | 0.19 | 0.27 | 0.49 | 0.15 | 0.15 | 1.00 |
Protein Official symbol | Source Organism | Tissue of Expression | Level of hypoxia | Altitude | Duration of experiment | Level of expression | Fold change | Experiment details | geographical location | ethnicity of the patients | Control group | Control (Fold change) | Reference (PMID) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CYBA | Human | Blood | - | 3250 m | 4 day | downregulated | -1.77 | Microarray | Himalayas | Indians | 1 | Sea level healthy individuals | 24465776 |
miRTarBase ID | miRNA | Species (miRNA) | Protein Official Symbol | Human Entrez ID | Species (Target Gene) | Experiments | Support Type | References (PMID) |
---|---|---|---|---|---|---|---|---|
MIRT044553 | hsa-miR-320a | Homo sapiens | CYBA | 1535 | Homo sapiens | CLASH | Functional MTI (Weak) | 23622248 |
MIRT046446 | hsa-miR-15b-5p | Homo sapiens | CYBA | 1535 | Homo sapiens | CLASH | Functional MTI (Weak) | 23622248 |
ID | GO ID | GO Term | GO Type |
---|---|---|---|
1535 | GO:0030307 | positive regulation of cell growth | GOTERM_BP_DIRECT |
1535 | GO:0033864 | positive regulation of NAD | GOTERM_BP_DIRECT |
1535 | GO:0017124 | Rab guanyl-nucleotide exchange factor activity | GOTERM_MF_DIRECT |
1535 | GO:0016021 | integral component of membrane | GOTERM_CC_DIRECT |
1535 | GO:0048010 | vascular endothelial growth factor receptor signaling pathway | GOTERM_BP_DIRECT |
1535 | GO:0005789 | endoplasmic reticulum membrane | GOTERM_CC_DIRECT |
1535 | GO:0045087 | innate immune response | GOTERM_BP_DIRECT |
1535 | GO:0045730 | respiratory burst | GOTERM_BP_DIRECT |
1535 | GO:0051279 | regulation of release of sequestered calcium ion into cytosol | GOTERM_BP_DIRECT |
1535 | GO:0071356 | cellular response to tumor necrosis factor | GOTERM_BP_DIRECT |
1535 | GO:1903428 | positive regulation of reactive oxygen species biosynthetic process | GOTERM_BP_DIRECT |
1535 | GO:1904385 | cellular response to angiotensin | GOTERM_BP_DIRECT |
1535 | GO:0016324 | apical plasma membrane | GOTERM_CC_DIRECT |
1535 | GO:0042493 | response to drug | GOTERM_BP_DIRECT |
1535 | GO:0001666 | response to hypoxia | GOTERM_BP_DIRECT |
1535 | GO:0014895 | smooth muscle hypertrophy | GOTERM_BP_DIRECT |
1535 | GO:0070555 | response to interleukin-1 | GOTERM_BP_DIRECT |
1535 | GO:0046872 | metal ion binding | GOTERM_MF_DIRECT |
1535 | GO:0030141 | secretory granule | GOTERM_CC_DIRECT |
1535 | GO:0030670 | phagocytic vesicle membrane | GOTERM_CC_DIRECT |
1535 | GO:0043025 | neuronal cell body | GOTERM_CC_DIRECT |
1535 | GO:0032760 | positive regulation of tumor necrosis factor production | GOTERM_BP_DIRECT |
1535 | GO:1904845 | cellular response to L-glutamine | GOTERM_BP_DIRECT |
1535 | GO:0005515 | protein binding | GOTERM_MF_DIRECT |
1535 | GO:0048661 | positive regulation of smooth muscle cell proliferation | GOTERM_BP_DIRECT |
1535 | GO:0071407 | cellular response to organic cyclic compound | GOTERM_BP_DIRECT |
1535 | GO:0005634 | nucleus | GOTERM_CC_DIRECT |
1535 | GO:1900426 | positive regulation of defense response to bacterium | GOTERM_BP_DIRECT |
1535 | GO:0002479 | antigen processing and presentation of exogenous peptide antigen via MHC class I | GOTERM_BP_DIRECT |
1535 | GO:0006954 | inflammatory response | GOTERM_BP_DIRECT |
1535 | GO:0032755 | positive regulation of interleukin-6 production | GOTERM_BP_DIRECT |
1535 | GO:0001725 | stress fiber | GOTERM_CC_DIRECT |
1535 | GO:0005739 | mitochondrion | GOTERM_CC_DIRECT |
1535 | GO:0005886 | plasma membrane | GOTERM_CC_DIRECT |
1535 | GO:0043020 | NADPH oxidase complex | GOTERM_CC_DIRECT |
1535 | GO:0006801 | superoxide metabolic process | GOTERM_BP_DIRECT |
1535 | GO:0034137 | positive regulation of toll-like receptor 2 signaling pathway | GOTERM_BP_DIRECT |
1535 | GO:0055114 | oxidation-reduction process | GOTERM_BP_DIRECT |
1535 | GO:0009055 | electron carrier activity | GOTERM_MF_DIRECT |
1535 | GO:0097038 | perinuclear endoplasmic reticulum | GOTERM_CC_DIRECT |
1535 | GO:0017004 | cytochrome complex assembly | GOTERM_BP_DIRECT |
1535 | GO:0001938 | positive regulation of endothelial cell proliferation | GOTERM_BP_DIRECT |
1535 | GO:0071333 | cellular response to glucose stimulus | GOTERM_BP_DIRECT |
1535 | GO:0071480 | cellular response to gamma radiation | GOTERM_BP_DIRECT |
1535 | GO:0000302 | response to reactive oxygen species | GOTERM_BP_DIRECT |
1535 | GO:0050766 | positive regulation of phagocytosis | GOTERM_BP_DIRECT |
1535 | GO:0071260 | cellular response to mechanical stimulus | GOTERM_BP_DIRECT |
1535 | GO:1904044 | response to aldosterone | GOTERM_BP_DIRECT |
1535 | GO:0016175 | phospholipase A2 activator activity | GOTERM_MF_DIRECT |
1535 | GO:0005768 | endosome | GOTERM_CC_DIRECT |
1535 | GO:0003106 | negative regulation of glomerular filtration by angiotensin | GOTERM_BP_DIRECT |
1535 | GO:0045454 | cell redox homeostasis | GOTERM_BP_DIRECT |
1535 | GO:0005925 | focal adhesion | GOTERM_CC_DIRECT |
1535 | GO:0032930 | positive regulation of superoxide anion generation | GOTERM_BP_DIRECT |
1535 | GO:0042554 | superoxide anion generation | GOTERM_BP_DIRECT |
1535 | GO:0046982 | protein heterodimerization activity | GOTERM_MF_DIRECT |
1535 | GO:0005794 | Golgi apparatus | GOTERM_CC_DIRECT |
1535 | GO:0030425 | dendrite | GOTERM_CC_DIRECT |
1535 | GO:0014823 | response to activity | GOTERM_BP_DIRECT |
1535 | GO:0031667 | response to nutrient levels | GOTERM_BP_DIRECT |
1535 | GO:0050665 | hydrogen peroxide biosynthetic process | GOTERM_BP_DIRECT |
1535 | GO:0070257 | positive regulation of mucus secretion | GOTERM_BP_DIRECT |
1535 | GO:0020037 | heme binding | GOTERM_MF_DIRECT |
1535 | GO:0016020 | membrane | GOTERM_CC_DIRECT |
Protein Official Symbol | Human Entrez ID | Disease Name | Disease Id | Disease Semantic Type | Semantic score | DSI | DPI | Disease Type |
---|---|---|---|---|---|---|---|---|
CYBA | 1535 | Kidney Failure | C0035078 | Disease or Syndrome | 0.3 | 0.55 | 0.655 | disease |
CYBA | 1535 | Diabetes Mellitus, Non-Insulin-Dependent | C0011860 | Disease or Syndrome | 0.4 | 0.55 | 0.655 | disease |
CYBA | 1535 | Kidney Failure, Chronic | C0022661 | Disease or Syndrome | 0.53 | 0.55 | 0.655 | disease |
CYBA | 1535 | Fibrosis, Liver | C0239946 | Disease or Syndrome | 0.3 | 0.55 | 0.655 | disease |
CYBA | 1535 | Streptozotocin Diabetes | C0038433 | Experimental Model of Disease | 0.3 | 0.55 | 0.655 | disease |
CYBA | 1535 | Diabetes Mellitus, Experimental | C0011853 | Experimental Model of Disease | 0.3 | 0.55 | 0.655 | disease |
CYBA | 1535 | Heart Diseases | C0018799 | Disease or Syndrome | 0.31 | 0.55 | 0.655 | group |
CYBA | 1535 | Hepatomegaly | C0019209 | Finding | 0.4 | 0.55 | 0.655 | phenotype |
CYBA | 1535 | Atherogenesis | C1563937 | Pathologic Function | 0.3 | 0.55 | 0.655 | phenotype |
CYBA | 1535 | Renal Insufficiency | C1565489 | Disease or Syndrome | 0.3 | 0.55 | 0.655 | disease |
CYBA | 1535 | Alloxan Diabetes | C0002152 | Experimental Model of Disease | 0.3 | 0.55 | 0.655 | disease |
CYBA | 1535 | Hypertensive disease | C0020538 | Disease or Syndrome | 0.6 | 0.55 | 0.655 | group |
CYBA | 1535 | Granulomatous Disease, Chronic, X-Linked | C1844376 | Disease or Syndrome | 0.31 | 0.55 | 0.655 | disease |
CYBA | 1535 | Liver Cirrhosis, Experimental | C0023893 | Experimental Model of Disease | 0.3 | 0.55 | 0.655 | disease |
CYBA | 1535 | Atherosclerosis | C0004153 | Disease or Syndrome | 0.4 | 0.55 | 0.655 | disease |
CYBA | 1535 | Liver Cirrhosis | C0023890 | Disease or Syndrome | 0.3 | 0.55 | 0.655 | disease |
CYBA | 1535 | Autosomal Recessive Chronic Granulomatous Disease | C3661525 | Disease or Syndrome | 0.33 | 0.55 | 0.655 | disease |
CYBA | 1535 | Chronic granulomatous disease | C0018203 | Disease or Syndrome | 0.7 | 0.55 | 0.655 | group |
CYBA | 1535 | Granulomatous Disease, Chronic, Autosomal Recessive, Cytochrome B-Negative | C1856255 | Disease or Syndrome | 0.6 | 0.55 | 0.655 | disease |
Protein Official Symbol | Human Entrez ID | drug_claim_primary_name | drug_name | drug_chembl_id | interaction_types |
---|